^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Ocrevus (ocrelizumab)

i
Other names: PRO 70769, R 1594, RG1594, rhuMab 2H7, PRO70769, OCR, RO4964913, PRO-70769, R1594, RO-4964913, RG 1594, RO 4964913, R-1594, RG-1594
Associations
Trials
Company:
Biogen, Roche
Drug class:
CD20 inhibitor
Related drugs:
Associations
Trials
12d
A Study on the Efficacy and Safety of Ocrelizumab and Rituximab in the Treatment of Refractory Myasthenia Gravis (ChiCTR2400084422)
P2, N=120, Completed, Peking University People's Hospital; Department of Neurology, Peking University People’s Hospital | Not yet recruiting --> Completed
Trial completion
|
Rituxan (rituximab) • Ocrevus (ocrelizumab)
12d
A Study on the Efficacy and Safety of Ocrelizumab in the Treatment of AchR Antibody Positive Generalized Myasthenia Gravis Patients (ChiCTR2400083807)
P2, N=124, Completed, Peking University People's Hospital; Department of Neurology, Peking University People’s Hospital | Not yet recruiting --> Completed
Trial completion
|
Ocrevus (ocrelizumab)
12d
A Study on the Efficacy and Safety of Ocrelizumab versus Tacrolimus in the Treatment of Newly Diagnosed Generalized Myasthenia Gravis Patients (ChiCTR2400083801)
P2, N=132, Completed, Peking University People's Hospital; Department of Neurology, Peking University People’s Hospital | Not yet recruiting --> Completed
Trial completion
|
Ocrevus (ocrelizumab)
15d
New P1 trial
|
IL2 (Interleukin 2)
|
cyclophosphamide • fludarabine IV • mesna • IDP-023 • Proleukin (aldesleukin) • Ocrevus (ocrelizumab)
22d
New trial
|
Ocrevus (ocrelizumab)
25d
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus (clinicaltrials.gov)
P=N/A, N=18, Completed, University of South Florida | Active, not recruiting --> Completed
Trial completion • Metastases
|
Ocrevus (ocrelizumab)
2ms
A Systems Approach to Understanding Disease Processes in Multiple Sclerosis (clinicaltrials.gov)
P=N/A, N=14, Completed, Providence Health & Services | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Nov 2023
Trial completion • Trial completion date
|
Ocrevus (ocrelizumab)
2ms
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical) (clinicaltrials.gov)
P=N/A, N=732, Completed, State University of New York at Buffalo | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Feb 2024
Trial completion • Trial completion date • Trial primary completion date
|
Ocrevus (ocrelizumab)
2ms
Enrollment change
|
Ocrevus (ocrelizumab)
4ms
O'HAND: A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (clinicaltrials.gov)
P3, N=1000, Recruiting, Hoffmann-La Roche | Trial completion date: Nov 2030 --> Jan 2028 | Trial primary completion date: Dec 2027 --> Jan 2025
Trial completion date • Trial primary completion date
|
Ocrevus (ocrelizumab)
4ms
DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov)
P4, N=800, Active, not recruiting, The Cleveland Clinic | Trial primary completion date: Apr 2030 --> Jul 2027
Trial primary completion date
|
Rituxan (rituximab) • Briumvi (ublituximab-xiiy) • fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)
4ms
Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf (clinicaltrials.gov)
P=N/A, N=168, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=240 --> 168
Enrollment closed • Enrollment change • Real-world evidence • Real-world
|
Ocrevus (ocrelizumab)
4ms
Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation. (PubMed, Brain)
Therapy with ocrelizumab, teriflunomide or dimethyl fumarate reduced EBV-specific, but not CMV-specific MHC-I-restricted TRB sequence matches. Together, this data suggests that the aberrant MHC-I-restricted T-cell response directed against EBV is specific to MS with regard to NMO, MOGAD and Susac's Syndrome and that it is specifically modified by MS treatments interfering with EBV host cells or activated lymphocytes.
Journal
|
CD8 (cluster of differentiation 8)
|
Ocrevus (ocrelizumab)
4ms
Short-term B-cell Depletion in Relapsing Multiple Sclerosis (clinicaltrials.gov)
P4, N=10, Completed, Johns Hopkins University | Active, not recruiting --> Completed
Trial completion
|
Ocrevus (ocrelizumab)
4ms
Enrollment open
|
Ocrevus (ocrelizumab)
4ms
New P4 trial • Immune cell
|
Ocrevus (ocrelizumab)
5ms
SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma. (PubMed, Vaccines (Basel))
Disease-modifying therapies (DMTs) impact the cellular immune response to severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccines in patients with multiple sclerosis (pwMS)...Therefore, the measurement of IL-2 and IL-5 levels could complement traditional IFN-γ assays to more comprehensively characterize the cellular responses to SARS-CoV-2 vaccines. Our results provide a comprehensive cytokine profile for pwMS receiving different DMTs and offer valuable insights for designing vaccination strategies in this patient population.
Journal • Viral vector
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL17A (Interleukin 17A) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
|
Ocrevus (ocrelizumab)
6ms
Mechanistic Study of Ocrevus (clinicaltrials.gov)
P=N/A, N=35, Completed, University of Michigan | Recruiting --> Completed
Trial completion
|
Ocrevus (ocrelizumab)
6ms
Enrollment open
|
Ocrevus (ocrelizumab)
6ms
CONSONANCE EXT: LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB (clinicaltrials.gov)
P3, N=72, Active, not recruiting, Centre Hospitalier Universitaire de Nice | Recruiting --> Active, not recruiting
Enrollment closed
|
Ocrevus (ocrelizumab)
6ms
DanNORMS: Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis (clinicaltrials.gov)
P3, N=600, Active, not recruiting, Rigshospitalet, Denmark | Recruiting --> Active, not recruiting | Trial completion date: Dec 2028 --> May 2028 | Trial primary completion date: Dec 2025 --> May 2026
Enrollment closed • Trial completion date • Trial primary completion date • Head-to-Head
|
FCER1G (Fc Fragment Of IgE Receptor Ig) • NEFL (Neurofilament Light Chain)
|
Ruxience (rituximab-pvvr) • Ocrevus (ocrelizumab) • methylprednisolone oral
7ms
OLERO: A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (clinicaltrials.gov)
P3, N=1300, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2029
Trial completion date • Trial primary completion date
|
Ocrevus (ocrelizumab)
7ms
DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov)
P4, N=800, Active, not recruiting, The Cleveland Clinic | Recruiting --> Active, not recruiting
Enrollment closed
|
Rituxan (rituximab) • Briumvi (ublituximab-xiiy) • fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)
7ms
Disrupting B and T cell Collaboration in Autoimmune Disease: T cell engagers versus CAR T cell therapy? (PubMed, Clin Exp Immunol)
Historically, B and T cell (B-T cell) co-interaction was targeted through different pathways such as alemtuzumab, abatacept, and dapirolizumab with variable impact on B cell depletion (BCD), whereas the majority of patients with AID including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and organ transplantation benefit from targeted BCD with anti-CD20 monoclonal antibodies such as rituximab, ocrelizumab or ofatumumab...In the treatment of cancer, chimeric antigen receptor (CAR) T cell therapy and T cell engagers (TCE) that recruit T cells to induce B cell cytotoxicity have delivered promising results for anti-CD19 CAR T cell therapies, the CD19 TCE blinatumomab and CD20 TCE such as mosunetuzumab, glofitamab or epcoritamab. Limited evidence suggests that anti-CD19 CAR T cell therapy may be effective in managing refractory AID whereas we await evaluation of TCE for use in non-oncological indications. Therefore, here, we discuss the potential mechanistic advantages of novel therapies that rely on T cells as effector cells to disrupt B-T cell collaboration toward overcoming rituximab-resistant AID.
Journal • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD27 (CD27 Molecule)
|
CD19 expression
|
Rituxan (rituximab) • Blincyto (blinatumomab) • Epkinly (epcoritamab-bysp) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • Ocrevus (ocrelizumab)
7ms
Trial primary completion date
|
Ocrevus (ocrelizumab)
7ms
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical) (clinicaltrials.gov)
P=N/A, N=732, Active, not recruiting, State University of New York at Buffalo | Trial primary completion date: Mar 2024 --> Jun 2024
Trial primary completion date
|
Ocrevus (ocrelizumab)
7ms
ORATORIO-CP: Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS (clinicaltrials.gov)
P=N/A, N=732, Active, not recruiting, State University of New York at Buffalo | Trial primary completion date: Mar 2024 --> Nov 2024
Trial primary completion date
|
Ocrevus (ocrelizumab)
7ms
Trial completion date
|
Ocrevus (ocrelizumab)
8ms
Trial primary completion date
|
Ocrevus (ocrelizumab)
8ms
Trial primary completion date • Head-to-Head
|
Ocrevus (ocrelizumab) • dexamethasone injection • methylprednisolone sodium succinate
8ms
A Systems Approach to Understanding Disease Processes in Multiple Sclerosis (clinicaltrials.gov)
P=N/A, N=14, Active, not recruiting, Providence Health & Services | Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
Ocrevus (ocrelizumab)
8ms
MINORE: A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy (clinicaltrials.gov)
P4, N=44, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
Enrollment closed
|
Ocrevus (ocrelizumab)
8ms
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) (clinicaltrials.gov)
P3, N=769, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2029 --> Mar 2029 | Trial primary completion date: Nov 2025 --> Apr 2025
Trial completion date • Trial primary completion date
|
Ocrevus (ocrelizumab)
9ms
PRECEPT: Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab (clinicaltrials.gov)
P3, N=19, Completed, Providence Health & Services | Active, not recruiting --> Completed | N=52 --> 19
Trial completion • Enrollment change
|
Ocrevus (ocrelizumab)
9ms
Trial completion
|
Ocrevus (ocrelizumab)
9ms
Trial completion date
|
Ocrevus (ocrelizumab)
9ms
Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI (clinicaltrials.gov)
P=N/A, N=60, Recruiting, Kessler Foundation | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
Ocrevus (ocrelizumab)
9ms
SOPRANINO: A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab (clinicaltrials.gov)
P4, N=20, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
Enrollment closed
|
Ocrevus (ocrelizumab)
10ms
OPA: Ocrelizumab for Psychosis by Autoimmunity (clinicaltrials.gov)
P1/2, N=40, Recruiting, The Methodist Hospital Research Institute | Unknown status --> Recruiting
Enrollment open
|
Ocrevus (ocrelizumab)
10ms
Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis (clinicaltrials.gov)
P=N/A, N=24, Completed, University of Maryland, Baltimore | Active, not recruiting --> Completed
Trial completion
|
Ocrevus (ocrelizumab)
10ms
WOE of Anti-CD20 Therapies (clinicaltrials.gov)
P=N/A, N=150, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
Enrollment open
|
Ocrevus (ocrelizumab)